Core Insights - Datavault AI Inc. has granted an exclusive worldwide license to Scilex Holding Company for its AI-driven technology, aimed at creating a Biotech Exchange platform for secure tokenization and monetization of biotech assets [1][2][3] - The agreement highlights the potential to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, providing an alternative for companies to secure non-dilutive funding [3][4] - Datavault AI's robust intellectual property portfolio includes key patents that support the secure tokenization and exchange of sensitive genetic information [4][6] Licensing Agreement Details - Datavault AI will receive a non-refundable upfront license fee of $10 million, paid in four installments of $2.5 million each by Scilex [6][8] - Additionally, Datavault AI is eligible for sales milestone payments of up to $2.55 billion based on Scilex achieving certain sales milestones [7][8] Technology and Market Potential - The technology licensed to Scilex is expected to extend into a Pharmaceutical Exchange platform, potentially transforming the pharmaceutical industry [2] - The tokenization opportunity in the pharmaceutical sector is significant, with estimates suggesting a market size of $2.0 trillion for drug sales and diagnostics [3][4] Intellectual Property and Innovations - Datavault AI's intellectual property includes a pending patent for "Platform and Method for Tokenizing DNA Data," which establishes a secure framework for tokenizing genetic information [4][6] - The company has a comprehensive suite of issued and pending patents that support the Biotech Exchange, enabling secure data handling and monetization [4][6] Previous Collaborations and Technological Advancements - The licensing agreement builds on Datavault AI's previous collaborations, including work with Brookhaven National Laboratory on biofuel research [5] - Datavault AI's technology suite is customizable and includes AI and Machine Learning automation, third-party integration, and detailed analytics [9]